Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 3, 1996, Pages 1073-1077

  Chiu, Noel ^a   Park, Ina ^a   Reid, Ian A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ISOPRENALINE; PHOSPHODIESTERASE INHIBITOR; RENIN; ROLIPRAM;

ANIMAL; ARTICLE; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; HEART RATE; MALE; METABOLISM; RABBIT; TIME;

ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; ISOPROTERENOL; MALE; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RABBITS; RENIN; ROLIPRAM; TIME FACTORS;

EID: 0030099028     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. BEAVO, J. A. AND REIFSNYDER, D H.: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. T.I.P.S. 11: 150-1990.
2. CONTI, M., JIN, S.-.L. C., MONACO, L., REPASKE, D. R. AND SWINNEN, J. V.: Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocrine Rev. 12: 218-234, 1991.
3. DAVIS, J. O. AND FREEMAN, R. H : Mechanisms regulating renin release. Physiol Rev. 56: 1-56, 1976.
4. DERIAN, C. K., SANTULLI, R. J., RAO, P. E., SOLOMON, H. F. AND BARRETT, J. A: Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J. Immunol. 154: 308-317, 1995.
5. DOWNING, G. J., POISNER, R. AND POISNER, A. M.: Beta-adrenoceptor activation stimulates, and phosphodiesterase inhibition potentiates, placental prorenin synthesis and release. J. Clin. Endocrinol. Metab. 78: 41-47, 1994.
6. FERNANDES, L. B., ELLIS, J. L. AND UNDEM, B. J.: Potentiation of nonadrenergic noncholinergic relaxation of human isolated bronchus by selective inhibitors of phosphodiesterase isozymes. Am. J Resp. Grit Care Med 150: 1384-1390, 1994.
7. GLANTZ, S. A., AND SLINKER, B. K.: Primer of Applied Regression and Analysis of Variance, McGraw-Hill, Inc , New York, 1990.
8. HACKENTHAL, E., PAUL, M., GANTEN, D. AND TAUGNER, R.: Morphology, physiology, and molecular biology of renin secretion. Physiol. Rev. 70: 1067-1116, 1990.
9. HEASLIP, R. J., BUCKLEY, S. K., SICKELS, B. D. AND GRIMES, D.: Bronchial us. cardiovascular activities of selective phosphodiesterase inhibitors in the anesthetized beta-blocked dog. J. Pharmcol. Exp. Ther. 257: 741-747, 1991.
10. HOEY, M. AND HOUSLAY, M. D.: Identification and selective inhibition of four distinct soluble forms of cyclic nucleotide phosphodiesterase activity from kidney. Biochem. Pharmacol. 40: 193-202, 1990.
11. HOFFMAN, B. B.: Adrenoceptor-activating and other sympathomimetic drugs. In Basic and Clinical Pharmacology, ed. by B. G. Katzung, pp. 115-131, Appleton and Lange, Connecticut, 1995.
12. HOLBROOK, M. AND COKER, S. J.: Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits. Br. J. Pharmacol. 103: 1973-1979, 1991.
13. JACKSON, E. K.: Adenosine: A physiological brake on renin release. Ann. Rev. Pharmacol. Toxicol. 31: 1-35, 1991.
14. KEETON, T. K. AND CAMPBELL, W. B.: The pharmacologic alteration of renin release. Pharmacol Rev. 32: 81-227, 1980.
15. KURTZ, A.: Cellular control of renin secretion. Rev. Physiol. Biochem. Pharmacol. 113: 2-40, 1989.
16. LUGNIER, C. AND KOMAS, N.: Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation. Eur. Heart J. 14:suppl.I, 141-148, 1993.
17. MASUOKA, H., ITO, M., NAKANO, T., NAKA, M. AND TANAKA, T.: Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney. J. Cardiovasc. Pharmacol. 15: 302-307, 1990.
18. MI, Z. C. AND JACKSON, E. K : Metabolism of exogenous cyclic AMP to adenosine in the rat kidney. J. Pharmacol. Exp. Ther. 273: 728-733, 1995
19. MENARD, J. AND CATT, K. J.: Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I. Endocrinology. 90: 422-430, 1972.
20. MURRAY, K J.: Methods in cyclic nucleotide research. In Intracellular Messengers, ed. by A. A. Boulton, G. B. Baker and C. W. Taylor, pp 313-368, Humana Press, New Jersey, 1992.
21. NICHOLSON, C. D., CHALLISS, R. A. J. AND SHAHID, M.: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. T.I P.S. 12: 19-27, 1991.
22. PANG, D. C.: Cyclic AMP and cyclic GMP phosphodiesterases: Target for drug development Drug Dev. Res. 12: 85-92, 1988.
23. RABE, K F., TENOR, H., DENT, G., SCHUDT, C., NAKASHIMA M. AND MAGNUSEN, H.: Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266: L536-L543, 1994.
24. 1 cells. Kidney Int. 41: 88-99, 1992.
25. REID, I. A.: Role of nitric oxide in the regulation of renin and vasopressin secretion. Front Neuroendoerinol. 15: 351-383, 1995.
26. REID, I. A., CHIU, T. AND CHOU, L.: Effect of inhibition of type III phosphodiesterase on renin secretion in conscious rabbits (Abstracts). International Conference on the Biochemistry and Molecular Biology of Nitric Oxide, University of California, Los Angeles. 100, 1994.
27. REID I. A., MORRIS, B. J. AND GANONG, W. F.: The renin-angiotensin system. Ann Rev. Physiol. 40: 377-410, 1978
28. REID, I. A., STOCKIGT, J. R., GOLDFIEN, A. AND GANONG, W. F.: Stimulation of renin secretion in dogs by theophylline. Eur. J. Pharmacol. 17: 325-332, 1972.
29. SIMPSON, P. J., SCHELM, J. A., SMALLWOOD, J. K., CLAY, M. P. AND LINDSTROM, T. D.: Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury. J. Cardiovasc. Pharmacol. 19: 987-995, 1992.
30. SKOTT, O. AND JENSEN, B. L.: Cellular and intrarenal control of renin secretion. Clin. Sci. 84: 1-10, 1993.
31. SUGIOKA, M., ITO, M., MASUOKA, H., ICHIKAWA, K., KONISHI, T., TANAKA, T. AND NAKANO, T.: Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes. Arch. Pharmacol. 350: 284-293, 1994.
32. TAKEDA, S., LIN, C.-T., MORGANO, P. G., MCINTYRE, S. J. AND DOUSA, T. P.: High activity of low-Michaelis-Menten constant 3′, 5′-cyclic adenosine monophosphate-phosphodiesterase isoenzymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus. Endocrinology 129: 287-294, 1991.
33. WARREN, J. B., WILSON, A. J., LOI, R. K. AND COUGHLAN, M. L.: Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J 7: 1394-1400, 1993.
34. YAMAKI, M., MCINTYRE, S., RASSIER, M. E., SCHWARTZ, J. H. AND DOUSA, T. P.: Cyclic 3′,5′-nucleotide diesterases in dynamics of cAMP and eGMP in rat collecting duct cells. Am. J. Physiol. 262: F957-F964, 1992.